Protection against Respiratory Syncytial Virus by a Recombinant Newcastle Disease Virus Vector

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Virology

• Publication date

  2006-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/JVI.80.3.1130-1139.2006PMID 16414990PMCID PMC1346968
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Economic Impact of Respiratory Syncytial Virus-Related Illness in the US

  2012cited by this paper
• Recombinant Newcastle Disease Virus as a Vaccine Vector for Cancer Therapy

  2008influential reference
• Respiratory syncytial virus and metapneumovirus

  2007cited by this paper
• Dendritic Cells and NK Cells Stimulate Bystander T Cell Activation in Response to TLR Agonists through Secretion of IFN-αβ and IFN-γ1

  2005cited by this paper
• Role for Innate IFNs in Determining Respiratory Syncytial Virus Immunopathology 1

  2005cited by this paper
• Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFN-alpha beta and IFN-gamma.

  2005cited by this paper
• Inhibition of Toll-Like Receptor 7- and 9-Mediated Alpha/Beta Interferon Production in Human Plasmacytoid Dendritic Cells by Respiratory Syncytial Virus and Measles Virus

  2005cited by this paper
• Isolation of cross-reactive, subtype-specific monoclonal antibodies against influenza virus HA1 and HA2 hemagglutinin subunits

  2005cited by this paper
• IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors.

  2005influential reference
• Type I Interferon as a Link Between Innate and Adaptive Immunity through Dendritic Cell Stimulation

  2004cited by this paper
• Suppression of the Induction of Alpha, Beta, and Gamma Interferons by the NS1 and NS2 Proteins of Human Respiratory Syncytial Virus in Human Epithelial Cells and Macrophages

  2004cited by this paper
• Identification and characterization of viral antagonists of type I interferon in negative-strand RNA viruses.

  2004cited by this paper
• Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection

  2004cited by this paper
• Suppression of the Induction of Alpha, Beta, and Lambda Interferons by the NS1 and NS2 Proteins of Human Respiratory Syncytial Virus in Human Epithelial Cells and Macrophages

  2004cited by this paper
• The future of respiratory syncytial virus vaccine development

  2004cited by this paper
• Recombinant Newcastle disease virus as a vaccine vector.

  2003cited by this paper
• Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon

  2003cited by this paper
• Nonstructural Proteins NS1 and NS2 of Bovine Respiratory Syncytial Virus Block Activation of Interferon Regulatory Factor 3

  2003cited by this paper
• Dendritic Cell Responses to Early Murine Cytomegalovirus Infection

  2003cited by this paper
• Overview of phase I studies of intravenous administration of PV701, an oncolytic virus.

  2003cited by this paper
• Adjuvants recognized by toll-like receptors inhibit the induction of polarized type 2 T cell responses by natural attachment (G) protein of respiratory syncytial virus.

  2003cited by this paper
• Newcastle Disease Virus V Protein Is a Determinant of Host Range Restriction

  2003cited by this paper
• Selective contribution of IFN-α/β signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection

  2003cited by this paper
• Selective contribution of IFN-alpha/beta signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection.

  2003influential reference
• The Development of Murine Plasmacytoid Dendritic Cell Precursors Is Differentially Regulated by FLT3-ligand and Granulocyte/Macrophage Colony-Stimulating Factor

  2002cited by this paper
• Respiratory syncytial virus infection suppresses lung CD8+ T-cell effector activity and peripheral CD8+ T-cell memory in the respiratory tract

  2002cited by this paper
• Natural Reinfection with Respiratory Syncytial Virus Does Not Boost Virus-Specific T-Cell Immunity

  2002cited by this paper
• Respiratory syncytial virus: reverse genetics and vaccine strategies.

  2002cited by this paper
• Paramyxovirus strategies for evading the interferon response

  2002cited by this paper
• RSV-induced immunopathology: dynamic interplay between the virus and host immune response.

  2002cited by this paper
• Respiratory Syncytial Virus (RSV) Nonstructural (NS) Proteins as Host Range Determinants: a Chimeric Bovine RSV with NS Genes from Human RSV Is Attenuated in Interferon-Competent Bovine Cells

  2002cited by this paper
• A Unique Mechanism for Innate Cytokine Promotion of T Cell Responses to Viral Infections1

  2002cited by this paper
• Pulmonary T cells induced by respiratory syncytial virus are functional and can make an important contribution to long‐lived protective immunity

  2002cited by this paper
• Respiratory syncytial virus vaccine development.

  2001cited by this paper
• A combination vaccine confers full protection against co-infections with influenza, herpes simplex and respiratory syncytial viruses.

  2001cited by this paper
• Respiratory syncytial virus infections in previously healthy working adults.

  2001cited by this paper
• Visualization and Characterization of Respiratory Syncytial Virus F-Specific CD8+ T Cells During Experimental Virus Infection1

  2001cited by this paper
• Recombinant Newcastle Disease Virus as a Vaccine Vector

  2001influential reference
• Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T cells.

  2001cited by this paper
• Interferons alpha and beta as immune regulators--a new look.

  2001cited by this paper
• Interferons α and β as Immune Regulators—A New Look

  2001cited by this paper
• The Attachment (G) Glycoprotein of Respiratory Syncytial Virus Contains a Single Immunodominant Epitope That Elicits Both Th1 and Th2 CD4+ T Cell Responses1

  2000cited by this paper
• Type I Interferon as a Powerful Adjuvant for Monocyte-Derived Dendritic Cell Development and Activity in Vitro and in Hu-Pbl-Scid Mice

  2000cited by this paper
• Type I Interferons Keep Activated T Cells Alive

  1999cited by this paper
• Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.

  1998cited by this paper
• Determinants and kinetics of cytokine expression patterns in lungs of vaccinated mice challenged with respiratory syncytial virus.

  1997cited by this paper
• Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine.

  1997cited by this paper
• Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease.

  1996cited by this paper
• Development

  1996cited by this paper
• Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern

  1996cited by this paper
• Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus

  1996cited by this paper
• Functional role of type I and type II interferons in antiviral defense.

  1994cited by this paper
• Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus.

  1993cited by this paper
• Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G.

  1992cited by this paper
• Reinfection of mice with respiratory syncytial virus

  1991cited by this paper
• Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins

  1989cited by this paper
• Respiratory Syncytial Virus

  1988cited by this paper
• Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus

  1988cited by this paper
• Primary respiratory syncytial virus infection in mice

  1988cited by this paper
• Risk of primary infection and reinfection with respiratory syncytial virus.

  1986cited by this paper
• Analysis of the Interferons Induced in Mice In Vivo and in Macrophages In Vitro by Newcastle Disease Virus and by Polyinosinic-Polycytidylic Acid

  1986cited by this paper
• Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children.

  1979cited by this paper
• Interferon production in children with respiratory syncytial, influenza, and parainfluenza virus infections.

  1978cited by this paper
• Interferon in nasal secretions from infants with viral respiratory tract infections.

  1978cited by this paper
• Interferon induction by Newcastle disease virus in mice.

  1970cited by this paper
• An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine.

  1969cited by this paper
• Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine.

  1969cited by this paper
• Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

  1969cited by this paper
• Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population.

  1969cited by this paper
• Multiplication of Newcastle disease virus strains and interferon production in the mouse, an animal naturally insusceptible to this infection.

  1966cited by this paper
• Multiplication of Newcastle disease virus strains and interferon production in the mouse, an animal naturally insusceptible to this infection.

  1966cited by this paper

• Progress in African Swine Fever Vector Vaccine Development

  2025cites this paper
• Development of an RT-qPCR and a Next-Generation Sequencing approach to assess viral shedding of NDV-based SARS-CoV-2 variant vaccines

  2025cites this paper
• Cotton Rat Model of Respiratory Syncytial Virus Infection.

  2025cites this paper
• Negative-Strand RNA Virus-Vectored Vaccines.

  2024cites this paper
• Advantages and challenges of Newcastle disease virus as a vector for respiratory mucosal vaccines.

  2023cites this paper
• Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico

  2023cites this paper
• Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases

  2023cites this paper
• Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico

  2022cites this paper
• Avian Orthoavulavirus Type-1 as Vaccine Vector against Respiratory Viral Pathogens in Animal and Human

  2022cites this paper
• Development and Scalable Production of Newcastle Disease Virus-Vectored Vaccines for Human and Veterinary Use

  2022influential citation
• Avian Paramyxovirus 4 Antitumor Activity Leads to Complete Remissions and Long-term Protective Memory in Preclinical Melanoma and Colon Carcinoma Models

  2022cites this paper
• Intranasal immunization with avian paramyxovirus type 3 expressing SARS-CoV-2 spike protein protects hamsters against SARS-CoV-2

  2022cites this paper
• Newcastle disease virus in poultry with an interface as a human vector

  2022cites this paper
• Mucosal delivery of RNA vaccines by Newcastle disease virus vectors

  2022cites this paper
• An intranasal recombinant NDV-BRSV Fopt vaccine is safe and reduces lesion severity in a colostrum-deprived calf model of RSV infection

  2022cites this paper
• Mucosal Delivery of Recombinant Vesicular Stomatitis Virus Vectors Expressing Envelope Proteins of Respiratory Syncytial Virus Induces Protective Immunity in Cotton Rats

  2021cites this paper
• Viral Vectors in Veterinary Vaccine Development: A Textbook

  2021cites this paper
• Engineering of Live Chimeric Vaccines against Human Metapneumovirus

  2020cites this paper
• Paramyxoviruses as Vaccine Vectors

  2020cites this paper
• Newcastle Disease Virus as a Vaccine Vector for 20 Years: A Focus on Maternally Derived Antibody Interference

  2020cites this paper
• Exploring the Prospects of Engineered Newcastle Disease Virus in Modern Vaccinology

  2020cites this paper
• Microbial community structure and composition is associated with host species and sex in Sigmodon cotton rats

  2020cites this paper
• Will Attention by Vaccine Developers to the Host’s Nuclear Hormone Levels and Immunocompetence Improve Vaccine Success?

  2019cites this paper
• A viral-vectored RSV vaccine induces long-lived humoral immunity in cotton rats.

  2018cites this paper
• Avian Paramyxovirus: A Brief Review

  2017cites this paper
• Newcastle disease virus-based MERS-CoV candidate vaccine elicits high-level and lasting neutralizing antibodies in Bactrian camels

  2017cites this paper
• Newcastle disease virus vectored vaccines as bivalent or antigen delivery vaccines

  2017cites this paper
• Newcastle Disease Virus as a Vaccine Vector for Development of Human and Veterinary Vaccines

  2016influential citation
• Distinct Roles of Type I and Type III Interferons in Intestinal Immunity to Homologous and Heterologous Rotavirus Infections

  2016cites this paper
• Robust Lys63-Linked Ubiquitination of RIG-I Promotes Cytokine Eruption in Early Influenza B Virus Infection

  2016cites this paper
• Rabies Control and Treatment: From Prophylaxis to Strategies with Curative Potential

  2016cites this paper
• Development of Acquired Immunity following Repeated Respiratory Syncytial Virus Infections in Cotton Rats

  2016cites this paper
• Recombinant Newcastle disease virus-vectored vaccines against human and animal infectious diseases.

  2015cites this paper
• Evaluation of humoral, mucosal, and cellular immune responses following co-immunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus

  2015cites this paper
• A recombinant varicella vaccine harboring a respiratory syncytial virus gene induces humoral immunity.

  2015cites this paper
• Type I Interferon Response Limits Astrovirus Replication and Protects against Increased Barrier Permeability In Vitro and In Vivo

  2015cites this paper
• Comparative analysis of anti-viral transcriptomics reveals novel effects of influenza immune antagonism

  2015cites this paper
• RNA-based viral vectors

  2015cites this paper
• Acute and Chronic Airway Disease After Human Respiratory Syncytial Virus Infection in Cotton Rats (Sigmodon hispidus).

  2015cites this paper
• Enveloped Viruses with Single-Stranded Negative RNA Genome as Objects and Subjects of VLP Nanotechnology

  2015cites this paper
• Induction of protective effector immunity to prevent pathogenesis caused by the respiratory syncytial virus. Implications on therapy and vaccine design

  2014cites this paper
• Newcastle Disease Virus Vector Producing Human Norovirus-Like Particles Induces Serum, Cellular, and Mucosal Immune Responses in Mice

  2014cites this paper
• An omics insight: A hope for HRSV vaccine

  2014cites this paper
• Effect of recombinant Newcastle disease virus transfection on lung adenocarcinoma A549 cells in vivo

  2014cites this paper
• Newcastle disease virus: Current status and our understanding

  2014cites this paper
• respiratory syncytial virus ( RSV ) vaccine based on parainfluenza irus 5 ( PIV 5 )

  2014cites this paper
• Boots for Achilles: Progesterone's Reduction of Cholesterol Is a Second-Order Adaptation

  2013cites this paper
• Rabies Virus Is Recognized by the NLRP3 Inflammasome and Activates Interleukin-1β Release in Murine Dendritic Cells

  2013cites this paper
• Rescue of recombinant Newcastle disease virus from cDNA.

  2013cites this paper
• Recent Advances in Diagnosis, Prevention, and Treatment of Human Respiratory Syncytial Virus

  2013cites this paper
• Evaluation of the Replication, Pathogenicity, and Immunogenicity of Avian Paramyxovirus (APMV) Serotypes 2, 3, 4, 5, 7, and 9 in Rhesus Macaques

  2013cites this paper
• Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses.

  2013cites this paper
• Recent developments with live‐attenuated recombinant paramyxovirus vaccines

  2013cites this paper
• The N500 Glycan of the Respiratory Syncytial Virus F Protein is Required for Fusion, but Not for Stabilization or Triggering of the Protein

  2013cites this paper
• Modulación de la síntesis de interferones en la infección por paramixovirus

  2013cites this paper
• Rift Valley Fever Virus Glycoproteins, Key to Entry and Control

  2013cites this paper
• Non-propagating, recombinant vesicular stomatitis virus vectors encoding respiratory syncytial virus proteins generate potent humoral and cellular immunity against RSV and are protective in mice.

  2013cites this paper
• Respiratory Syncytial Virus: Rodent Models and Vaccine Development

  2012influential citation
• The role of dendritic cells in innate and adaptive immunity to respiratory syncytial virus, and implications for vaccine development

  2012cites this paper
• Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.

  2012cites this paper
• Targeting RSV with vaccines and small molecule drugs.

  2012cites this paper
• Need for a safe vaccine against respiratory syncytial virus infection

  2012cites this paper
• Protective Efficacy of Newcastle Disease Virus Expressing Soluble Trimeric Hemagglutinin against Highly Pathogenic H5N1 Influenza in Chickens and Mice

  2012cites this paper
• Current progress on development of respiratory syncytial virus vaccine.

  2011cites this paper
• Honey as an antiviral agent against respiratory syncytial virus

  2011cites this paper
• Experimental Infection of Mice with Avian Paramyxovirus Serotypes 1 to 9

  2011cites this paper
• Respiratory Syncytial Virus Infection in Adults

  2011cites this paper
• Live Attenuated Vaccines for Respiratory Syncytial Virus

  2011cites this paper
• Parenteral vaccination of mammalian livestock with Newcastle disease virus-based vector vaccines offers optimal efficacy and safety

  2011cites this paper
• Newcastle Disease Virus Expressing Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Induces Strong Mucosal and Serum Antibody Responses in Guinea Pigs

  2011cites this paper
• The vaccines for Bovine Herpesvirus Type 1: A review

  2011cites this paper
• A host-restricted viral vector for antigen-specific immunization against Lyme disease pathogen

  2011cites this paper
• Experimental infection of hamsters with avian paramyxovirus serotypes 1 to 9

  2011cites this paper
• Newcastle Disease Virus-Vectored Rabies Vaccine Is Safe, Highly Immunogenic, and Provides Long-Lasting Protection in Dogs and Cats

  2011cites this paper
• An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children

  2011cites this paper
• Soluble Respiratory Syncytial Virus Fusion Protein in the Fully Cleaved, Pretriggered State, a Tool to Study Protein Triggering

  2011cites this paper
• Respiratory syncytial virus vaccine development

  2011cites this paper
• Rabies Virus Infection Induces Type I Interferon Production in an IPS-1 Dependent Manner While Dendritic Cell Activation Relies on IFNAR Signaling

  2010cites this paper
• Type I Interferons Mediate the Innate Cytokine Response to Recombinant Fowlpox Virus but Not the Induction of Plasmacytoid Dendritic Cell-Dependent Adaptive Immunity

  2010cites this paper
• Pharmacologic advances in the treatment and prevention of respiratory syncytial virus.

  2010cites this paper
• Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1

  2010cites this paper
• Recombinant respiratory syncytial virus F protein expression is hindered by inefficient nuclear export and mRNA processing

  2010cites this paper
• Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector.

  2010cites this paper
• Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus.

  2010cites this paper
• Lambda Interferon Is the Predominant Interferon Induced by Influenza A Virus Infection In Vivo

  2010cites this paper
• Antiviral Response Dictated by Choreographed Cascade of Transcription Factors

  2010cites this paper
• Induction of Type I Interferon Secretion through Recombinant Newcastle Disease Virus Expressing Measles Virus Hemagglutinin Stimulates Antibody Secretion in the Presence of Maternal Antibodies

  2010cites this paper
• Innate immune mechanisms of controlling respiratory virus infection.

  2010cites this paper
• De novo generation of a non-segmented negative strand RNA virus with a bicistronic gene.

  2009cites this paper
• Viral Vectors

  2009cites this paper
• Respiratory syncytial virus vaccine development.

  2009cites this paper
• RSV fusion (F) protein DNA vaccine provides partial protection against viral infection.

  2009cites this paper
• Challenges in developing a pediatric RSV vaccine

  2009cites this paper
• Recombinant Vectors as Influenza Vaccines

  2009cites this paper
• Replikationsdefektive flavivirus-impfstoffe und impfstoffvektoren

  2009cites this paper
• Vaccins de flavivirus défaillant sur le plan de la réplication et vecteurs de vaccin

  2009cites this paper
• Receptores de la inmunidad innata en procesos infecciosos pulmonares

  2009cites this paper
• TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity.

  2009cites this paper
• Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans

  2009cites this paper
• Recombinant Newcastle Disease Virus as a Vaccine Vector for Cancer Therapy

  2008cites this paper